Abstract

The antidepressant actions of deep brain stimulation (DBS) are associated with progressive neuroadaptations within the mood network, modulated in part, by neurotrophic mechanisms. We investigated the antidepressant-like effects of chronic nucleus accumbens (NAc) DBS and its association with change in glycogen synthase kinase 3 (GSK3) and mammalian target of rapamycin (mTOR) expression in the infralimbic cortex (IL), and the dorsal (dHIP) and ventral (vHIP) subregions of the hippocampus of antidepressant resistant rats. Antidepressant resistance was induced via daily injection of adrenocorticotropic hormone (ACTH; 100 μg/day; 15 days) and confirmed by non-response to tricyclic antidepressant treatment (imipramine, 10 mg/kg). Portable microdevices provided continuous bilateral NAc DBS (130 Hz, 200 μA, 90 μs) for 7 days. A control sham electrode group was included, together with ACTH- and saline-treated control groups. Home cage monitoring, open field, sucrose preference, and, forced swim behavioral tests were performed. Post-mortem levels of GSK3 and mTOR, total and phosphorylated, were determined with Western blot. As previously reported, ACTH treatment blocked the immobility-reducing effects of imipramine in the forced swim test. In contrast, treatment with either active DBS or sham electrode placement in the NAc significantly reduced forced swim immobility time in ACTH-treated animals. This was associated with increased homecage activity in the DBS and sham groups relative to ACTH and saline groups, however, no differences in locomotor activity were observed in the open field test, nor were any group differences seen for sucrose consumption across groups. The antidepressant-like actions of NAc DBS and sham electrode placements were associated with an increase in levels of IL and vHIP phospho-GSK3β and phospho-mTOR, however, no differences in these protein levels were observed in the dHIP region. These data suggest that early response to electrode placement in the NAc, irrespective of whether active DBS or sham, has antidepressant-like effects in the ACTH-model of antidepressant resistance associated with distal upregulation of phospho-GSK3β and phospho-mTOR in the IL and vHIP regions of the mood network.

Highlights

  • Deep brain stimulation (DBS) is capable of generating long–lasting neuroadaptations, some of which may contribute to its therapeutic benefits in refractory psychiatric illness (Herrington et al, 2016)

  • This study provides further support for the antidepressant actions of nucleus accumbens (NAc) DBS using reduced immobility in the forced swim test as our primary proxy of antidepressant efficacy

  • adrenocorticotropic hormone (ACTH)-pretreated animals treated with NAc DBS remained immobile for significantly less time relative to control ACTHtreated rats (ADR)

Read more

Summary

Introduction

Deep brain stimulation (DBS) is capable of generating long–lasting neuroadaptations, some of which may contribute to its therapeutic benefits in refractory psychiatric illness (Herrington et al, 2016). The nucleus accumbens (NAc) is a common target for DBS therapy across a range of disorders. The NAc has been proposed as a potential target for the treatment of anxiety, obesity, binge eating disorder, and schizophrenia (Doucette et al, 2015; Ho et al, 2015; Gault et al, 2018). The mechanisms through which chronic NAc DBS can facilitate therapeutic response across distinct treatment-refractory psychiatric conditions are poorly understood. The location and function of the NAc within the broader mesocorticolimbic circuitry may help to explain its seemingly diverse clinical utility in some of the most difficult to treat patient populations

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call